Psychedelics Investing Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder 02 September
Psychedelics Investing Compass Pathways to Participate in Four Investor Conferences in September 27 August
